neurology

News

Lundbeck announces plans to cut a fifth of R&D workforce

Lundbeck has announced plans to cut its research and development team, which could lead to a reduction of up to 160 jobs from an 800-strong department.

News

Novartis offers reimbursement options as EU backs costly SMA...

Novartis’ AveXis unit has said European regulators have approved its Zolgensma (onasemnogene abeparvovec) gene therapy for the rare childhood wasting disease spinal muscular atrophy (SMA),

News

Takeda posts surprise profit a year after Shire mega-merger

Japan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year ago, as the company shakes off the huge debts it incurred to get the deal done.

News

Illustration of a nerve cell on a colored background with light effects

Newron's shares dive after rare disease drug failure

Newron’s share price has collapsed after the biotech axed development of its drug sarizotan for the rare genetic brain disorder Rett Syndrome following the failure of a key trial.

News

Neurocrine delays US Parkinson's drug launch amid COVID disr...

The FDA has approved Ongentys, an oral Parkinson’s Disease drug from US biotech Neurocrine Biosciences, which can be added to prolong the effects of standard therapy and help prevent “off”

Views & Analysis

Eisai and Alexa skills in epilepsy: the pharmaphorum podcast

Voice technology like Amazon’s Alexa is taking some big steps forward in healthcare and in the pharmaceutical world one of the companies working in this area is Eisai.

Lundbeck announces plans to cut a fifth of R&D workforce

Novartis offers reimbursement options as EU backs costly SMA...

Takeda posts surprise profit a year after Shire mega-merger

Newron's shares dive after rare disease drug failure

Neurocrine delays US Parkinson's drug launch amid COVID disr...

Eisai and Alexa skills in epilepsy: the pharmaphorum podcast

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

neurology

Editor's Picks